Go Deep
Astellas Pharma Inc.
Astellas Pharma Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,899 | 12.2 | 2.32 | 0.30 | 1,522.49 |
Astellas Pharma Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 640,914,000,000.0 | 537,925,000,000.0 | 571,206,000,000.0 | 524,320,000,000.0 |
| Net Profit | 141,828,000,000.0 | 43,521,000,000.0 | 100,379,000,000.0 | 79,213,000,000.0 |
| EPS | 79.2 | — | — | — |
Astellas Pharma Inc. Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 2,139,245,000,000.0 | 1,912,323,000,000.0 | 1,603,672,000,000.0 | 1,518,619,000,000.0 |
| Net Profit | 291,535,000,000.0 | 50,747,000,000.0 | 17,045,000,000.0 | 98,714,000,000.0 |
| EPS | 162.8 | 28.4 | 9.5 | 54.2 |
Astellas Pharma Inc. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total Assets | 3,567,042,000,000.0 | 3,339,544,000,000.0 | 3,569,603,000,000.0 | 2,456,518,000,000.0 |
| Total Liabilities | 1,736,158,000,000.0 | 1,826,289,000,000.0 | 1,973,615,000,000.0 | 948,564,000,000.0 |
| Total Equity | 1,829,044,000,000.0 | 1,513,255,000,000.0 | 1,595,988,000,000.0 | 1,507,954,000,000.0 |
Astellas Pharma Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 8.2%Receivables 20.9%Inventory 9.3%Fixed assets (tangible) 10.0%Intangible assets 40.3%Long-term investments 0.6%Other assets 10.7%
How it's funded — Mar 2026
Short-term debt 6.9%Long-term debt 9.0%Payables 5.6%Other liabilities 27.2%Shareholders' equity 51.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 291,177.0 | 218,313.0 | 364,471.0 | 396,624.0 |
| Receivables | 746,808.0 | 632,525.0 | 534,985.0 | 427,965.0 |
| Inventory | 331,014.0 | 297,261.0 | 248,738.0 | 174,386.0 |
| Fixed assets (tangible) | 358,424.0 | 328,921.0 | 293,742.0 | 286,459.0 |
| Intangible assets | 1,438,107.0 | 1,538,921.0 | 1,872,518.0 | 890,907.0 |
| Long-term investments | 20,297.0 | 18,989.0 | 15,684.0 | 12,689.0 |
| Other assets | 381,215.0 | 304,614.0 | 239,465.0 | 267,488.0 |
| Liabilities & equity | ||||
| Short-term debt | 245,952.0 | 266,533.0 | 472,278.0 | 75,000.0 |
| Long-term debt | 320,000.0 | 564,893.0 | 447,738.0 | 50,000.0 |
| Payables | 199,752.0 | 187,840.0 | 185,193.0 | 140,236.0 |
| Other liabilities | 970,454.0 | 807,023.0 | 868,406.0 | 683,328.0 |
| Shareholders' equity | 1,830,884.0 | 1,513,255.0 | 1,595,988.0 | 1,507,954.0 |
| Net tangible assets | 390,937.0 | -25,666.0 | -276,530.0 | 617,047.0 |
Astellas Pharma Inc. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 560,188,000,000.0 | 194,512,000,000.0 | 172,475,000,000.0 | 327,767,000,000.0 | — |
| Investing Activities | -66,722,000,000.0 | -89,419,000,000.0 | -845,802,000,000.0 | -84,500,000,000.0 | — |
| Financing Activities | -404,779,000,000.0 | -261,367,000,000.0 | 614,060,000,000.0 | -195,623,000,000.0 | — |